ERIS LIFESCIENCES LIMITED
Latest filings
- Q2 and H1 FY27 earnings call recording now available · Investor Communications
- Eris Q2 FY27: revenue up 12.6%, profit up 39.2%, margin recovery ahead · Investor Communications
- Q2 FY27 revenue up 13%, PAT up 39%; Rs 35.9 cr write-down hits profit · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Sells branded pharmaceutical formulations in India across ten therapy areas, with cardiac, oral anti-diabetics (OAD), biologics and insulins among the largest contributors. The domestic branded formulations (DBF) business grew 14% year-on-year in Q1 FY27 to Rs 801 cr, with seven of ten therapies delivering double-digit growth. A biologics and insulin manufacturing facility at Bhopal is scheduled to commercialise in August 2026, intended to support future insulin aspart and other analogue launches. A semaglutide brand (Sanghi) launched in Q1 FY27 captured 20% volume share and 14% value share in its launch quarter, while an earlier GLP-1 brand (Sundae) ranks #1 in prescriptions with about 21% share. The company also runs a Swiss parenteral operation under EU GMP remediation and an export franchise, both smaller contributors. Consolidated Q1 FY27 revenue was Rs 873 cr at a 34% EBITDA margin; FY26 full-year revenue was Rs 3,129 cr at a 35.5% EBITDA margin.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ERIS LIFESCIENCES LIMITED's filed financials and exchange disclosures
What does ERIS LIFESCIENCES LIMITED do?
ERIS LIFESCIENCES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ERIS.
Is ERIS LIFESCIENCES LIMITED profitable?
Yes. Over the trailing twelve months ERIS LIFESCIENCES LIMITED reported a net profit of ₹666 Cr on revenue of ₹3,230 Cr.
Does ERIS LIFESCIENCES LIMITED pay a dividend?
Not in the latest reported year — ERIS LIFESCIENCES LIMITED's dividend payout for FY26 was nil.
Is ERIS LIFESCIENCES LIMITED debt-free?
No. It reported borrowings of ₹2,310 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹2,255 Cr after cash. Debt stands at 0.59× equity. That is higher than 86% of its 166 Pharmaceuticals peers.
Is ERIS LIFESCIENCES LIMITED expensive compared with its peers?
On trailing P/E, ERIS LIFESCIENCES LIMITED ranks 63 of 158 in Pharmaceuticals — cheaper than 61% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the ERIS LIFESCIENCES LIMITED share price move in a day?
On a typical session ERIS LIFESCIENCES LIMITED moves 0.96% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track ERIS LIFESCIENCES LIMITED's announcements?
Every NSE and BSE filing by ERIS LIFESCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.